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Abstract: OBJECTIVE A multidisciplinary heart valve team is recommended for the evaluation of treat-
ment in patients with valvular heart disease, but evidence supporting this concept is lacking. In patients
with severe mitral regurgitation, we thought to analyse the patient selection process by the heart team
for different treatment options and the outcome after treatment. METHODS In this single-centre cohort
study, all patients treated for mitral regurgitation between July 2013 and September 2018 were included.
Primary end points during follow-up were all-cause mortality and a combined end point, consisting of all-
cause mortality, cardiovascular rehospitalisation and mitral valve reintervention. RESULTS 179 patients
(44.8%) were treated using Mitraclip, 185 (46.2%) by surgical repair and 36 (9.0%) by surgical replace-
ment. The mortality risk according to EuroScore II differed significantly between treatment groups
(6.6%±5.6%, 1.7%±1.5% and 3.6%±2.7% for Mitraclip, surgical repair and replacement, respectively,
p<0.001). In-hospital mortality for the 3 groups were 3.4%, 1.6% and 8.3%, respectively (p=0.091).
Overall, surgical repair patients had higher 4-year survival (HR 0.40 (95% CI 0.26 to 0.63), p<0.001) and
fewer combined end points (HR 0.51 (95% CI 0.32 to 0.80), p<0.001) compared with surgical replacement
and Mitraclip patients. However, patients undergoing Mitraclip for isolated, primary mitral regurgitation
achieved very good long-term survival. CONCLUSION The multidisciplinary heart team assigned only
low-risk patients with favourable anatomy to surgical repair, while high-risk patients underwent Mitraclip
or surgical replacement. This strategy was associated with lower than expected in-hospital mortality for
Mitraclip patients and high 4-year survival rates for patients undergoing surgical or percutaneous repair
of isolated primary mitral regurgitation.
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Key questions
What is already known about this subject?
 ► According to current guidelines, a multidisciplinary 
heart valve team is recommended for the evaluation 
of treatment in patients with severe valvular heart 
disease; however, there is a lack of data supporting 
this approach, and the decision- making process is 
not well defined.
What does this study add?
 ► In this single- centre cohort study including 400 pa-
tients, we thought to analyse the patient selection 
process by the heart team for different treatment 
options in patients with mitral valve regurgitation 
and the outcome after treatment.
 ► The multidisciplinary heart team assigned only low- 
risk patients with favourable anatomy to surgical 
repair, while high- risk patients underwent Mitraclip 
or surgical replacement.
 ► This strategy was associated with lower than ex-
pected in- hospital mortality for Mitraclip patients 
and high 4- year survival rates for patients under-
going surgical or percutaneous repair of isolated 
primary mitral regurgitation.
How might this impact on clinical practice?
 ► A consequent selection process by the heart team 
requires reduction of factors often biassing treat-
ment assignment.
 ► In view of future treatment options including per-
cutaneous mitral valve replacement, the heart team 
selection process becomes even more important 
and may influence patient outcome.
ABSTRACT
Objective A multidisciplinary heart valve team is 
recommended for the evaluation of treatment in patients 
with valvular heart disease, but evidence supporting 
this concept is lacking. In patients with severe mitral 
regurgitation, we thought to analyse the patient selection 
process by the heart team for different treatment options 
and the outcome after treatment.
Methods In this single- centre cohort study, all patients 
treated for mitral regurgitation between July 2013 and 
September 2018 were included. Primary end points during 
follow- up were all- cause mortality and a combined end 
point, consisting of all- cause mortality, cardiovascular 
rehospitalisation and mitral valve reintervention.
Results 179 patients (44.8%) were treated using 
Mitraclip, 185 (46.2%) by surgical repair and 36 (9.0%) 
by surgical replacement. The mortality risk according 
to EuroScore II differed significantly between treatment 
groups (6.6%±5.6%, 1.7%±1.5% and 3.6%±2.7% for 
Mitraclip, surgical repair and replacement, respectively, 
p<0.001). In- hospital mortality for the 3 groups were 
3.4%, 1.6% and 8.3%, respectively (p=0.091). Overall, 
surgical repair patients had higher 4- year survival (HR 
0.40 (95% CI 0.26 to 0.63), p<0.001) and fewer combined 
end points (HR 0.51 (95% CI 0.32 to 0.80), p<0.001) 
compared with surgical replacement and Mitraclip 
patients. However, patients undergoing Mitraclip for 
isolated, primary mitral regurgitation achieved very good 
long- term survival.
Conclusion The multidisciplinary heart team assigned 
only low- risk patients with favourable anatomy to surgical 
repair, while high- risk patients underwent Mitraclip or 
surgical replacement. This strategy was associated with 
lower than expected in- hospital mortality for Mitraclip 
patients and high 4- year survival rates for patients 
undergoing surgical or percutaneous repair of isolated 
primary mitral regurgitation.
INTRODUCTION
Patients undergoing surgical treatment for 
mitral regurgitation (MR) have been studied 
for decades. In selected patient populations 
(relatively young patients, primary MR), 
surgical mitral valve repair (MVrepair) leads 
to outstanding repair rates and excellent 
long- term survival.1 2 However, in patients 
with secondary MR, and in particular in 
ischaemic heart disease, it is an ongoing 
debate whether surgical MVrepair or mitral 
valve replacement (MVR) is the treatment 
of choice.3 In addition, for elderly patients 
outcomes after mitral valve (MV) surgery 
are far less favourable.4 Percutaneous MV 
repair using the Mitraclip (MC) procedure 
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Figure 1 Decision- making algorithm of the heart team compared with estimated and experienced in- hospital mortality. MDT, 
multidisciplinary heart team; MR, mitral regurgitation; MV, mitral valve; MVR, surgical MV replacement.
has proven to be a treatment alternative for surgical high- 
risk patients with MR.5 6 However, these specific cohorts 
or randomised trials exclude many patients seen in daily 
practice, and single surgeon experiences in few, highly 
specialised centres may not represent reality in large parts 
of the world where patients are evaluated and treated by 
heart teams.
The concept of an multidisciplinary heart team (MDT) 
has evolved to a central role in modern cardiovascular 
care to ensure the most appropriate individual treatment 
and to improve the outcome for each patient.7 However, 
evidence supporting such an approach is lacking, in 
particular for MV regurgitation.8 Furthermore, the exact 
patient selection process performed by the MDT has not 
been described. The aim of this study was to report the 
selection process and the outcomes of patients under-




In this retrospective cohort analysis, all patients treated 
for MR at the Heart Clinic Zurich between July 2013 and 
September 2018 were included. Three patients treated 
with percutaneous valve- in- valve/ring replacement 
were excluded as they have been reported elsewhere.9 
Surgical treatment included isolated or combined MV 
surgery (MV surgery plus coronary bypass and/or addi-
tional valve surgery). In the percutaneous group, inter-
ventions counted as combined instead of isolated if the 
MC procedure was part of a beforehand planned series 
of interventions, including percutaneous coronary and/
or other valve interventions. Clinical data, including 
follow- up data, were extracted from patient charts and 
by telephone interview. Twelve patients were lost to 
follow- up. Echocardiographic parameters were quanti-
fied according to current guidelines.10 11
MDT decision
The MDT of the Heart Clinic Zurich consists of cardiac 
surgeons (two dedicated MV surgeons with >600 MVre-
pair operations each), interventional cardiologists (three 
experienced in MC procedure, main operator with >500 
MC interventions), imaging and heart failure specialists 
as well as cardiac anaesthetists. The MDT meets weekly 
to discuss all heart valve cases and works as an organisa-
tionally and financially independent unit. In cases of disa-
greement between the team members regarding optimal 
treatment, decision is taken according to the majority 
principle of present team members.
According to current guidelines, the MDT assigned 
all patients to one of the three treatment strategies 
(MC, surgical MVrepair or primary MV replacement (I° 
MVR)).8 12 The primary MDT’s treatment intention was 
surgical MVrepair. Anatomical amenability for MVrepair 
was analysed using three- dimensional transoesophageal 
echocardiography.13 For patients deemed high risk for 
surgery but with suitable MV anatomy, percutaneous 
MV repair using MC was performed.14 Patients were 
considered ‘high surgical risk’ based on a combination 
of factors, including estimated mortality (EuroScore II) 
>4%, age >80 years and additional clinical risk factors not 
3Külling M, et al. Open Heart 2020;7:e001280. doi:10.1136/openhrt-2020-001280
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  Age (years) 80.3 (8.1) 65.8 (11.6) 70.4 (11.1) <0.001
  Male sex, n (%) 105 (58.7) 127 (68.6) 13 (36.1) 0.001
  EuroScore II, (%) 6.6 (5.6) 1.7 (1.5) 3.6 (2.7) <0.001
  STS score mortality, (%) 4.6 (4.0) 1.0 (1.0) 3.2 (2.1) <0.001
  Body mass index (kg/cm2) 24.6 (4.5) 24.7 (3.4) 25.7 (4.6) 0.354
  Systolic blood pressure (mm Hg) 122.4 (22.5) 133.2 (17.5) 130.4 (22.4) <0.001
  Heart rate (bpm) 77.8 (17.5) 73.2 (15.7) 75.8 (15.4) 0.040
  Atrial fibrillation, n (%) 62 (36.9) 31 (17.1) 9 (26.5) <0.001
  NYHA ≥III, n (%) 160 (92.0) 45 (27.6) 14 (45.2) <0.001
Labaratory findings
  Haemoglobin (g/L) 125.4 (18.9) 138.8 (13.5) 130.7 (16.2) <0.001
  GFR (mL/min) 49.9 (19.4) 77.7 (14.3) 70.6 (20.9) <0.001
  NTproBNP (pg/mL) 10‘998.6 (30‘986.7) 677.1 (1’024.1) 2‘203.8 (2‘265.8) 0.014
History of
  Hypertension, n (%) 139 (77.7) 78 (42.2) 17 (47.2) <0.001
  Diabetes mellitus, n (%) 23 (12.8) 2 (1.1) 3 (8.3) <0.001
  Coronary artery disease, n (%) 96 (53.6) 40 (21.6) 11 (30.6) <0.001
  Percutaneous coronary intervention, n (%) 68 (38.0) 15 (8.1) 2 (5.6) <0.001
  Coronary bypass graft surgery, n (%) 28 (15.6) 0 (0.0) 2 (5.6) <0.001
  Prior mitral valve intervention, n (%) 8 (4.5) 2 (1.1) 5 (13.9) 0.001
  Stroke, n (%) 16 (8.9) 9 (4.9) 0 (0.0) 0.074
  Chronic obstructive pulmonary disease, n (%) 25 (14.0) 4 (2.2) 1 (2.8) <0.001
Mitral regurgitation
  ≥Moderate mitral regurgitation, n (%) 179 (100.0) 185 (100.0) 34 (94.4) <0.001
  Severe mitral regurgitation, n (%) 165 (92.2) 170 (91.9) 31 (86.1) 0.478
Aetiology of mitral regurgitation
  Primary, n (%) 102 (57.0) 175 (94.6) 30 (83.3) <0.001
  Secondary, n (%) 64 (35.7) 9 (4.9) 4 (11.1) <0.001
  Combination, n (%) 13 (7.3) 1 (0.5) 2 (5.6) 0.004
Further echocardiographic findings
  LVEF (%) 50.7 (16.4) 62.6 (7.4) 59.5 (10.3) <0.001
  LVEDVi (mL/m2) 82.4 (39.2) 75.0 (21.4) 73.7 (23.4) 0.070
  LAVI (mL/m2) 71.4 (29.0) 64.5 (30.3) 65.9 (19.0) 0.101
  RV function reduced, n (%) 66 (39.3) 11 (6.4) 4 (12.5) <0.001
  RV/RA pressure gradient 38.9 (13.5) 29.0 (12.7) 32.6 (11.3) <0.001
  ≥Moderate tricuspid regurgitation, n (%) 53 (31.0) 28 (15.7) 7 (20.0) 0.003
  ≥Moderate aortic stenosis, n (%) 6 (3.6) 2 (1.1) 3 (9.1) 0.036
  ≥Moderate aortic regurgitation, n (%) 14 (8.2) 9 (5.0) 5 (15.2) 0.105
GFR, glomerular filtration rate; LAVI, left atrial volume index; LVEDVi, left ventricular end diastolic volume index; LVEF, Left ventricular ejection 
fraction; MC, Mitraclip; MV, mitral valve; MVR, surgical MV replacement; MVrepair, surgical mitral valve repair; NTproBNP, N- terminated 
pro- brain natriuretic peptide; NYHA, New York Heart Association; RV, right ventricular; RV/RA, right ventricular/right atrial; STS, Society of 
Thoracic Surgeons.
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Table 3 Echocardiographic findings at discharge
MC (n=173) MVrepair (n=182) MVR (n=33) P value
LVEF (%) 48.2 (16.0) 56.6 (8.4) 56.7 (7.9) <0.001
LVEDVi (mL/m2) 79.5 (38.4) 55.7 (16.2) 51.1 (11.4) <0.001
LAVI (mL/m2) 68.4 (25.1) 48.6 (28.0) 50.6 (13.4) <0.001
≥Moderate mitral regurgitation, n (%) 34 (19.7) 4 (2.2) 0 (0.0) <0.001
Mean mitral gradient (mm Hg) 3.9 (1.7) 3.1 (1.2) 4.5 (1.6) <0.001
RV/RA pressure gradient 35.6 (9.4) 24.5 (6.9) 23.8 (6.3) <0.001
Heart rate (bpm) 74.7 (11.5) 80.6 (13.9) 81.5 (16.4) <0.001
Haemoglobin (g/dL) 10.8 (1.6) 10.8 (1.6) 10.1 (1.5) 0.034
Results given as mean values (±SD) except for mitral regurgitation.
LAVI, left atrial volume index; LVEDVi, left ventricular end diastolic volume index; LVEF, left ventricular ejection fraction; MC, Mitraclip; MV, mitral 
valve; MVR, surgical MV replacement; MVrepair, surgical mitral valve repair; RV/RA, right ventricular/right atrial.
covered by EuroScore II such as frailty, obesity or liver 
disease. If neither MVrepair nor MC seemed feasible 
according to anatomical criteria, or the surgical repair 
effort appeared unreasonably high, primary MV replace-
ment was performed.
In-hospital outcome
In- hospital outcome was measured as success of the initial 
treatment strategy and in terms of mortality. ‘Treatment 
success’ in surgical patients was defined as survival with 
residual MR ≤mild, no secondary MVR and absence of 
MV stenosis at discharge. The term ‘secondary’ MVR was 
used for patients in whom primary MVrepair failed and 
the surgical team decided intraoperatively to convert to 
MVR. Absence of mitral stenosis was defined as mean 
transvalvular gradient <5 mm Hg, or a gradient ≥5 mm 
Hg when haemodynamically explained by heart rate 
and/or haemoglobin level. In MC patients, a residual 
MR ≤moderate at discharge with a reduction in MR by ≥1 
grade from baseline was still considered as success. Pure 
technical success for MC patients was defined according 
to the M- VARC criteria.5 15
Follow-up outcome
Primary end points during follow- up were all- cause 
mortality and a combined endpoint, consisting of all- 
cause mortality, cardiovascular rehospitalisation and MV 
reintervention.
Secondary end points during follow- up were severity of 
MR and dyspnoea according to the New York Heart Asso-
ciation classification (NYHA) after 3 months, 1 year and 
at the last follow- up examination before January 2019. 
Secondary end points were analysed separately for the 
accomplished intervention at discharge (MC, MVrepair 
or all MVR).
Statistical analysis
Continuous data are expressed as mean±SD, and cate-
gorical data as number and percentage (%). To compare 
data, we used the t- test, one- way analysis of variance 
(ANOVA) or repeated measures ANOVA, as appropriate. 
The Kaplan- Meier survival curves were constructed to 
estimate event- free survival for different subgroups and 
were compared with the log rank (Mantel- Cox) test. 
Univariate and multivariate Cox- regression model was 
used to analyse the predictors on combined end points. 
The conditional average treatment effect was estimated 
for various subgroups of patients as the difference 
in probability of a combined end point within 1 year 
between MVrepair and MC using an augmented inverse 
probability weighted estimate. Both the treatment and 
outcome model were fitted with a Random Forest regres-
sion and a missForest imputation was used for 5.9% 
missing covariate values, while the width of the CIs was 
approximated using Bootstrap. The level of significance 
was set at a p value of <0.05. All statistical analyses were 
performed using SPSS software (V.25.0, SPSS, Chicago, 
Illinois, USA) and R (V.3.4.1).
RESULTS
MDT decision and baseline characteristics
Figure 1 demonstrates the assignment to the initial treat-
ment strategy. Seventy- five per cent of MVrepair and 
55% of MVR patients had isolated MV surgery. Baseline 
characteristics are summarised in table 1. Within the MC 
population, 57.0% of patients were treated for primary 
(EuroScore II 5.2%) and 35.7% for secondary MR 
(EuroScore II 9.0%). Of patients assigned to MVrepair, 
only 4.9% were treated for secondary MR (EuroScore II 
3.1%).
In-hospital outcome
Treatment success rates at discharge for the initial treat-
ment strategy MC, MVrepair and MVR were 84.9%, 89.7% 
and 91.7%, respectively (p=0.284). The treatment success 
rate for patients who underwent minimally invasive MVre-
pair for isolated MR was 93.6%. For MC patients, the 
technical success rate according to the M- VARC criteria 
was 99.4%.
One MC patient (0.6%) and 12 MVrepair patients 
(6.5%) needed peri- interventional conversion to MV 
replacement (secondary MVR) and were counted as 
failure of initial treatment strategy. Anatomical and 
Open Heart
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Figure 2 Long- term all- cause mortality and combined end points of the overall cohort (A and B), of Mitraclip patients 
according to the mitral regurgitation (MR) aetiology (C and D), and of patients with a primary MR who received an isolated 
repair, either by Mitraclip or surgically (E and F).
peri- interventional factors associated with treatment 
success (or failure) for the three treatment arms are 
summarised in table 2. Of note, staged percutaneous 
interventions did not impact initial MC treatment success, 
while concomitant surgical procedures, in particular 
aortic valve replacement, were more frequent in patients 
in whom the surgical treatment strategy failed. A calcified 
leaflet and/or annulus was more frequent in patients in 
whom surgical MVrepair failed but had no impact on MC 
or MVR treatment success.
The median (IQR) duration of hospital stay was 5 
(4–7.5) days for MC, 10 (9–12) days for MVrepair and 12 
(10–19.3) days for MVR. Echocardiographic findings at 
discharge are summarised in table 3.
In- hospital mortality of MC, MVrepair and MVR was 
3.4%, 1.6% and 8.3%, respectively, p=0.091 (figure 1).
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Table 4 Predictors for combined end points
MC (n=179) MVrepair (n=185)
P value HR 95% CI P value HR 95% CI
Univariate
  Age >75 years 0.607 0.866 0.500 to 1.499 0.030 2.463 1.094 to 5.547
  Height <170 cm 0.505 0.860 0.553 to 1.339 0.034 2.376 1.067 to 2.593
  Female 0.166 0.723 0.457 to 1.144 0.087 2.018 0.904 to 4.508
  NYHA ≥3 0.426 1.286 0.591 to 2.799 0.106 2.043 0.860 to 4.853
  EuroScore II >2.5% 0.033 2.324 1.069 to 5.050 0.002 3.602 1.613 to 8.044
  Atrial fibrillation 0.900 0.970 0.607 to 1.553 0.173 1.845 0.764 to 4.453
  Anaemia 0.047 1.565 1.006 to 2.436 0.027 2.893 1.132 to 7.396
  GRF <60 mL/min 0.093 1.551 0.930 to 2.587 0.147 2.093 0.772 to 5.676
  LVEF <60% 0.002 2.315 1.377 to 3.894 0.564 0.760 0.300 to 1.930
  LVEDVi >75 mL/m2 0.015 1.810 1.121 to 2.921 0.138 0.519 0.218 to 1.236
  RV function reduced <0.001 2.324 1.465 to 3.668 0.207 2.189 0.650 to 7.358
  RV/RA gradient >30 mm Hg 0.929 0.975 0.562 to 1.693 0.125 2.024 0.822 to 4.981
Multivariate
  EuroScore II >2.5% 0.116 1.966 0.845 to 4.572 0.007 3.759 1.437 to 9.832
  Anaemia 0.043 1.631 1.015 to 2.620 0.662 1.312 0.446 to 3.858
  LVEF <60% 0.025 2.015 1.091 to 3.723 – – –
  RV function reduced 0.016 1.871 1.125 to 3.109 – – –
GFR, glomerular filtration rate; LVEDVi, left ventricular end diastolic volume index; LVEF, Left ventricular ejection fraction; MC, Mitraclip; 
MVrepair, surgical mitral valve repair; NYHA, New York Heart Association; RV, right ventricular; RV/RA, right ventricular/right atrial.
Long-term outcome according to initial treatment strategy
Outcomes of the entire cohort during the mean follow- up 
time of 32.2±17.6 months are reported in figure 2A,B. 
Single and multivariate regression analysis of factors 
predicting combined end points in MC and MVrepair 
patients are summarised in table 4.
When analysing the long- term impact of treatment 
success at discharge, failure of initial treatment strategy 
did not influence all- cause mortality for MC or MVrepair 
patients but led to more combined end points in MC 
patients (HR 0.528, 95% CI 0.289 to 0.964, p=0.034).
Concomitant heart treatments as well as MR aetiology 
were additional factors influencing outcome. Patients 
with combined surgical or percutaneous interventions 
had a significantly higher all- cause mortality compared 
with patients with an isolated MV intervention (surgical 
MV treatment: HR 3.419, 95% CI 1.300 to 8.993, p=0.008; 
MC patients: HR 2.753, 95% CI 1.569 to 4.832, p<0.001). 
Furthermore, MC patients with secondary MR had a worse 
outcome compared with MC patients with a primary MR 
(figure 2C,D). And in the subgroups of patients with 
primary MR with an isolated MV treatment (figure 2E,F), 
the 4- year mortality rates were particularly low in MC 
patients. Women older than 75 years with small body size 
appear to profit from the MC procedure when analysing 
for combined end points at 1 year (figure 3).
The secondary follow- up end points MR grade and 




The concept of an interdisciplinary MDT is a centrepiece 
in modern structural heart disease treatment. Yet, there 
is no consensus on how the MDT should decide, and 
evidence supporting the effectiveness of MDT decisions 
for patients with severe MR is lacking. In our cohort study, 
we describe the selection process and outcome of an all- 
comer population with severe MR treated by a dedicated 
valvular MDT. Counter to the expectations generated 
by valvular guidelines, the percentage of MR patients 
assigned to (gold standard) surgical MVrepair was only 
46.2%, while 44.8% received percutaneous repair by MC 
and 9.0% of patients were eligible for primary MVR. In the 
only other published cohort of patients with MV disease 
treated according to the MDT decision, the distribution 
was similar (23% percutaneous and 62% surgical MV 
repair, 15% MVR).16 In our cohort, mainly patients with 
primary MR, favourable repair anatomy and low surgical 
risk were offered surgical MVrepair, while patients with 
elevated risk or secondary MR were treated percutane-
ously. Such a consequent selection process was achieved 
as our MDT has reduced factors often biassing treatment 
assignment such as patient referral to a specific doctor or 
financial interest of the individual MDT members.
As additional treatment options such as percutaneous 
MV replacement will be available in the future, selecting 
the right patient for the right treatment will be even more 
challenging.17 18 Percutaneous MVR by compassionate 
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Figure 3 Subgroup analysis to evaluate whether MVrepair or Mitraclip may be better for patients with isolated, primary MR. 
GFR, glomerular filtration rate; LAVI, left atrial volume index; LVEDVi, left ventricular end diastolic volume index; LVEF, left 
ventricular ejection fraction; MC, Mitraclip; MV, mitral valve; MVrepair, surgical mitral valve repair; RV/RA, rightventricular/right 
atrial.
Figure 4 Mitral regurgitation grade (MR) and dyspnoea (New York Heart Association (NYHA) I–IV) from baseline to the last 
follow- up examination according to the treatment performed. MC, Mitraclip.
use of TAVR prostheses as valve- in- valve or valve- in- 
ring showed lower than expected peri- interventional 
mortality and acceptable mid- term survival in highly 
selected patients.9 19 Whether the prostheses specifically 
designed for transcatheter MVR will improve outcome 
in patients at high risk for treatment failure (ie, calci-
fied leaflets or annulus, high surgical risk) remains to 
be seen.20
9Külling M, et al. Open Heart 2020;7:e001280. doi:10.1136/openhrt-2020-001280
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Effectiveness of the MDT treatment decision and room for 
improvement
The most important question is whether the MDT decision 
was the right one for the given patient. According to our 
data, patients assigned to MC achieved a lower in- hospital 
mortality than expected with surgical treatment, while 
patients assigned to surgical repair experienced in- hos-
pital mortality rates that met the expectations according 
to EuroScore II. This was particularly relevant for patients 
with secondary MR treated by MC, where the reduction 
of the expected to the achieved in- hospital mortality was 
largest. Our consequent selection process thus improved 
the short- term outcome of high- risk surgical patients by 
assigning them to the lower risk percutaneous treatment 
option. Furthermore, the benefit of the less invasive 
percutaneous treatment seemed particularly relevant for 
MC patients who had isolated, primary MR. Long- term 
survival rates of these patients was excellent and better 
than in most previously published series.21 22 In addition, 
this study corroborates previous data showing a negative 
impact of concomitant heart treatments on long- term 
survival and thus emphasises the importance of a careful 
selection process by the MDT.23
The best treatment option for short elderly patients 
remains controversial. This study suggests that 1 year 
outcome for women with an age >75 years and small 
height (as well as patients with a calcified annulus) 
might have been further improved if a percutaneous 
approach had been chosen. Reduced MVrepair rates 
in women have previously been reported24 and are 
possibly due to the lack of repair space in shorter elderly 
women with smaller annular dimensions and limited 
MV prolapse tissue. Two recent propensity- weighted 
analyses between surgical and percutaneous MV repair 
in elderly patients came to opposing conclusions, one 
favouring surgery and one favouring the percutaneous 
approach.25 26 The reasons for these discrepant results 
are unclear and need further analysis by randomised 
controlled trials.
Limitation
This study has the limitations attributed to its retrospec-
tive design and data collection. In addition, the decision- 
making process was not defined ‘a priori’ but represents 
the common understanding of our MDT. We cannot 
exclude that additional factors may have influenced deci-
sions and outcome.
The small number of patients assigned to MVR did 
prevent further statistical analyses. It may also account 
for the higher than expected in- hospital mortality in this 
group (one expected, three actual deaths), a mortality 
rate comparable to the 5.4% operative mortality in 
a large series of patients undergoing MVR.27 It does, 
however, underscore the need for lower- risk percu-
taneous MV replacement options for this high- risk 
surgical group.
A similar limitation has to be acknowledged regarding 
patients with secondary MR. Our team opted for surgical 
treatment in only 13 patients (9 MVrepair, 4 MVR), as 
opposed to 64 patients with secondary MR treated by 
MC. Therefore, this study cannot answer the question 
which treatment option is best for functional MR.
As we are a tertiary referral centre, patients not 
eligible for surgical or percutaneous treatment options 
are sent back to the primary cardiologist for optimal 
medical care. These (overall few) patients were not 
included in our study and we do not have follow- up 
data on them.
Conclusion
This study describes the MDT selection process in 
assigning patients for MR treatment and relates it to 
outcome. Only low- risk patients with favourable anatomy 
were offered MVrepair, while high- risk patients under-
went MC or MVR. This strategy was associated with lower 
than expected in- hospital mortality for MC patients and 
high 4- year survival rates for MVrepair and MC patients 
with isolated primary MR.
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